Market capitalization | $69.07m |
Enterprise Value | $-16.98m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.36 |
EV/Sales (TTM) EV/Sales | -5.01 |
P/S ratio (TTM) P/S ratio | 20.37 |
P/B ratio (TTM) P/B ratio | 0.76 |
Revenue growth (TTM) Revenue growth | -86.84% |
Revenue (TTM) Revenue | $3.39m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a Werewolf Therapeutics Inc forecast:
6 Analysts have issued a Werewolf Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 3.39 3.39 |
87%
87%
|
|
Gross Profit | 1.55 1.55 |
93%
93%
|
|
EBITDA | -64 -64 |
69%
69%
|
EBIT (Operating Income) EBIT | -66 -66 |
63%
63%
|
Net Profit | -62 -62 |
67%
67%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Werewolf Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Dan Hicklin |
Employees | 47 |
Founded | 2017 |
Website | www.werewolftx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.